StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Newly initiated interventional clinical trials in period by Year

Newly initiated interventional clinical trials in period (trials)

Moderna Newly initiated interventional clinical trials in period: 13.00 trials in FY2025, down 18.7% from a year earlier.

Latest, FY2025
13.00
Period ended Dec 31, 2025
Change on a year earlier
-18.7%
16.00 in FY2024
History
8 years
Since FY2018
Sources
1
ClinicalTrials.gov API v2 (ModernaTX, Inc.)

Where the FY2025 figure comes from

Source: ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Reported in ClinicalTrials.gov API v2 (ModernaTX, Inc.).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNewly initiated interventional clinical trials in period (trials)Year on yearSource
FY2025Dec 31, 202513.00-18.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2024Dec 31, 202416.00-27.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2023Dec 31, 202322.00+10.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2022Dec 31, 202220.00+5.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2021Dec 31, 202119.00+216.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2020Dec 31, 20206.000.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2019Dec 31, 20196.00+500.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
FY2018Dec 31, 20181.00–ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Cite this data

StockData. (2026). Moderna Newly initiated interventional clinical trials in period, annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ctgov-new-interventional

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.